Deals
Allergan Weighs Return to Deals With $34 Billion From Teva Sale
- CEO says company will look at anything `growth-oriented'
- Sale of generics unit to Teva not affected by U.S. tax rules
Allergan CEO Saunders on Acquisition Targets
This article is for subscribers only.
The end of the health-care industry’s biggest ever merger may also be the beginning of another round of deal-making for Allergan Plc.
“We will look at anything that is a growth-oriented asset,” Allergan Chief Executive Officer Brent Saunders said in a Bloomberg Television interview Wednesday, declining to specify potential targets. “That will include R&D assets and marketed products. Everything is a possibility.”